Skip to main content
Journal of Genetic Engineering and Biotechnology
Fig. 5 | Journal of Genetic Engineering and Biotechnology

Fig. 5

From: Pangenome diversification and resistance gene characterization in Salmonella Typhi prioritized RfaJ as a significant therapeutic marker

Fig. 5

A Virtual screening of FDA library against RfaJ, showing the most docked compound at the binding score of −6kcal/mol (brown peak), B high docked compounds (having a binding score higher than −6 kcal/mol) compared to the total number of compounds, C high docked compound along with the shortlisted four compounds, i.e., DB00549 (Zafirlukast), DB15637 (Fluzoparib), DB15688 (Zavegepant), and DB12411 (Bemcentinib)

Back to article page